Literature DB >> 20140101

A review of cardiovascular risks associated with medications used to treat type-2 diabetes mellitus.

Erin L St Onge, Carol Anne Motycka, Shannon A Miller.   

Abstract

Entities:  

Year:  2009        PMID： 20140101      PMCID： PMC2799105     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


× No keyword cloud information.
  39 in total

Review 1.  Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003.

Authors:  Richard W Nesto; David Bell; Robert O Bonow; Vivian Fonseca; Scott M Grundy; Edward S Horton; Martin Le Winter; Daniel Porte; Clay F Semenkovich; Sidney Smith; Lawrence H Young; Richard Kahn
Journal:  Circulation       Date:  2003-12-09       Impact factor: 29.690

2.  Cardiovascular disease in diabetes.

Authors:  Zachary T Bloomgarden
Journal:  Diabetes Care       Date:  2008-06       Impact factor: 19.112

3.  Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis.

Authors:  Sonal Singh; Yoon K Loke; Curt D Furberg
Journal:  JAMA       Date:  2007-09-12       Impact factor: 56.272

4.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.

Authors:  D M Nathan; S Genuth; J Lachin; P Cleary; O Crofford; M Davis; L Rand; C Siebert
Journal:  N Engl J Med       Date:  1993-09-30       Impact factor: 91.245

5.  Glucose control and vascular complications in veterans with type 2 diabetes.

Authors:  William Duckworth; Carlos Abraira; Thomas Moritz; Domenic Reda; Nicholas Emanuele; Peter D Reaven; Franklin J Zieve; Jennifer Marks; Stephen N Davis; Rodney Hayward; Stuart R Warren; Steven Goldman; Madeline McCarren; Mary Ellen Vitek; William G Henderson; Grant D Huang
Journal:  N Engl J Med       Date:  2008-12-17       Impact factor: 91.245

6.  Thiazolidinediones and cardiovascular outcomes in older patients with diabetes.

Authors:  Lorraine L Lipscombe; Tara Gomes; Linda E Lévesque; Janet E Hux; David N Juurlink; David A Alter
Journal:  JAMA       Date:  2007-12-12       Impact factor: 56.272

Review 7.  Diabetic myocardial disease: pathophysiology, early diagnosis and therapeutic options.

Authors:  Dimitrios Z Mytas; Pavlos N Stougiannos; Michael N Zairis; Stefanos G Foussas; Vlassios N Pyrgakis; Ioannis A Kyriazis
Journal:  J Diabetes Complications       Date:  2008-04-16       Impact factor: 2.852

8.  Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial.

Authors:  Steven E Nissen; Stephen J Nicholls; Kathy Wolski; Richard Nesto; Stuart Kupfer; Alfonso Perez; Horacio Jure; Robert De Larochellière; Cezar S Staniloae; Kreton Mavromatis; Jacqueline Saw; Bo Hu; A Michael Lincoff; E Murat Tuzcu
Journal:  JAMA       Date:  2008-03-31       Impact factor: 56.272

Review 9.  Homocysteine and coronary atherosclerosis.

Authors:  E L Mayer; D W Jacobsen; K Robinson
Journal:  J Am Coll Cardiol       Date:  1996-03-01       Impact factor: 24.094

10.  Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials.

Authors:  A Michael Lincoff; Kathy Wolski; Stephen J Nicholls; Steven E Nissen
Journal:  JAMA       Date:  2007-09-12       Impact factor: 56.272
View more
  2 in total

1.  Temporal Trend of the Prevalence of Modifiable Risk Factors of Stroke: An Ecological Study of Brazilians between 2006 and 2012.

Authors:  Laércio da Silva Paiva; Luiz Vinicius de Alcantara Sousa; Fernando Rocha Oliveira; Luis Eduardo Werneck de Carvalho; Rodrigo Daminello Raimundo; João Antonio Correa; Luiz Carlos de Abreu; Fernando Adami
Journal:  Int J Environ Res Public Health       Date:  2022-05-06       Impact factor: 4.614

2.  Athero-protective actions of two oral antidiabetic drugs: Suppression of inflammation and oxidative stress.

Authors:  Kan Chen
Journal:  J Cardiovasc Dis Res       Date:  2012-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.